|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese Society of Clinical Oncology(CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021(English version)显示文摘1. General guidelines2. Diagnosis3. Staging4. Treatment4.1 Diffuse large B-cell lymphoma(DLBCL)4.2 Follicular lymphoma(FL)4.3 Mantle cell lymphoma(MCL)4.4 Marginal zone lymphoma(MZL)4.5 Burkitt lymphoma(BL)4.6 CLL/Small lymphocytic lymphoma(SLL)4.7 Extra-nodal natural killer/T-cell lymphoma(ENKTCL), nasal type4.8 Peripheral T-cell lymphoma(PTCL)4.9 HL4.10 Primary central nervous system lymphoma5. Prognosis Lymphomas are a group of heterogeneous diseases. | Jun Zhu Jun Ma Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology Zhixiang Shen Zifen Gao Huiqiang Huang Xiaoqiu Li Yexiong Li Lugui Qiu Weili Zhao Qingyuan Zhang | 2021 | Chinese Journal of Cancer Research2021，33，3： | 18 |
| 2 | Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenstr(o)m macroglobulinemia显示文摘 | Yi Shuhua Cui Rui Li Zengjun An Gang Qi Junyuan Zou Dehui Zhang Peihong Chen Huishu Wang Jianxiang Chang Hong Qiu Lugui | 2014 | Chinese Medical Journal2014，，12： | 12 |
| 3 | Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China显示文摘Objective:This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia(CLL)and a 17p deletion(17p-)and identify the predictive factors within this subgroup.Methods:The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22,13q14 and 17p13;trisomy of bands 12q13;and translocation involving band 14q32.The data from 456 patients with or without a 17p-were retrospectively collected and analyzed.Results:The overall response rate(ORR)in patients with a 17p-was 56.9%,and patients with a high percentage of 17p-(defined as more than 25%of cells harbouring a 17p-)had a lower ORR.The median overall survival(OS)in patients with a 17p-was 78.0 months,which was significantly shorter than the OS in patients without this genetic abnormality(median 162.0 months,P<0.001).Within the subgroup with a 17p-,the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase(LDH),B symptoms,unmutated IGHV and a high percentage of 17p-.Conclusions:These results indicated that patients with a 17p-CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics. | Heng Li Wenjie Xiong Huimin Liu Shuhua Yi Zhen Yu Wei Liu Rui Lyu Tingyu Wang Dehui Zou Zengjun Li Lugui Qiu | 2017 | Chinese Journal of Cancer Research2017，29，2： | 6 |
| 4 | Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia显示文摘好攻击的 NK 房间白血病(ANKL ) 是在从亚洲的人之中是更流行的 NK 房间瘤的一种稀罕形式并且中央并且南美洲。病人们通常在天以内死到月,甚至在收到迅速的治疗学的管理以后。这里,我们由集成整个染色体执行了 ANKL 的第一全面研究, transcriptome 并且定序指向,象功能的试金一样的 cytokine 数组。在 JAK-STAT 小径的变化在 48% 被识别(14/29 ) ANKL 病人,当细胞外的 STAT3 激发器 IL10 被 56 褶层的一般水准提高时(P < 0.0001 ) 在检查的所有病人的血浆。另外的经常变异的基因包括的 TP53 (34%) , TET2 (28%) , CREBBP (21%) 和 MLL2 (21%) 。耐心的 NK 白血病房间在多重新陈代谢的小径显示出 STAT3 phosphorylation, MYC 表示和 transcriptional 活动的突出的激活。机能上地, STAT3 激活和 MYC 表示为 ANKL 房间的增长和幸存是批评的。发信号的 STAT 调整了发信号的 MYC 抄写节目,和两 STAT, MYC 抄写被要求维持核苷酸合成和 glycolysis 的激活。一起, JAK-STAT 小径在 ANKL 为 genomic 改变和 IL10 刺激代表一个主要目标。这最新发现的 JAK/STAT-MYC-biosynthesis 轴可以在对待白血病的这种子类型为新奇治疗学的策略的发展提供机会。 | Liang Huang Dan Liu Na Wang Shaoping Ling Yuting Tang Jun Wu Lingtong Hao Hui Luo Xuelian Hu Lingshuang Sheng Lijun Zhu Di Wang Yi Luo Zhen Shang Min Xiao Xia Mao Kuangguo Zhou Lihua Cao Lili Dong Xinchang Zheng Pinpin Sui Jianlin He Shanlan Mo Jin Yan Qilin Ao Lugui Qiu Hongsheng Zhou Qifa Liu Hongyu Zhang Jianyong Li Jie Jin Li Fu Weili Zhao Jieping Chen Xin Du Guoliang Qing Hudan Liu Xin Liu Gang Huang Ding Ma Jianfeng Zhou Qian-fei Wang | 2018 | Cell Research2018，28，2： | 5 |
| 5 | Phase Ⅱ open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma显示文摘Background: Despite the recent development of new therapies, multiple myeloma(MM) remains an incurable disease. Thus, new, efective treatments are urgently needed, particularly for relapsed or refractory MM(RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) that is currently in clinical development for the treatment of hematologic malignancies, i.e., circularly permuted TRAIL(CPT), was well tolerated at a dose of 2.5 mg/kg per day and showed promising preliminary activity in patients with RRMM. This phase II, open-label, multicenter study further investigated the eicacy and safety of 2.5-mg/kg per day CPT as single-agent therapy for patients with RRMM.Methods: Patients with RRMM were treated once daily with CPT(2.5 mg/kg, intravenously) for 14 consecutive days for each 21-day cycle. Clinical response and toxicity were assessed after each treatment cycle.Results: Twenty-seven patients received CPT. Using the European Group for Blood and Marrow Transplantation criteria, we calculated the overall response rate of 33.3% with 1 near-complete response(n CR) and 8 partial responses(PRs). The clinical beneit rate(48.1%) included 1 nCR, 8 PRs, and 4 minimal responses. The most common treatmentrelated adverse events(TRAEs) were fever, aspartate aminotransferase elevation, alanine aminotransferase elevation, leucopenia, rash, neutropenia, and thrombocytopenia. We graded toxicity using the Common Toxicity Criteria for Adverse Events, version 3.0, and determined that 37.0% of patients had at least 1 grade 3–4 TRAE.Conclusions: CPT as a single agent can elicit a response in patients with RRMM and is well tolerated. Further clinical investigation is warranted. | Yun Leng Lugui Qiu Jian Hou Yaozhong Zhao Xuejun Zhang Shifang Yang Hao Xi Zhongxia Huang Ling Pan Wenming Chen | 2016 | Chinese Journal of Cancer2016，35，12： | 4 |
| 6 | Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma显示文摘 | Fei Li Mu Hao Xiaoyan Feng Meirong Zang Yu Qin Shuhua Yi Zengjun Li Yan Xu Lili Zhou Weiwei Sui Shuhui Deng Dehui Zou Fenghuang Zhan Lugui Qiu | 2015 | Leukemia Research2015，，7： | 1 |
| 7 | Low serum mi R ‐19a expression as a novel poor prognostic indicator in multiple myeloma显示文摘 | Mu Hao Meirong Zang Erik Wendlandt Yan Xu Gang An Dasen Gong Fei Li Fang Qi Yanru Zhang Ye Yang Fenghuang Zhan Lugui Qiu | 2015 | Int. J. Cancer2015，，8： | 1 |
| 8 | Polymorphisms in folate-related genes: impact on risk of adult acute lymphoblastic leukemia rather than pediatric in Han Chinese显示文摘 | Lin Yang Liang Liu Jianxiang Wang Lugui Qiu Yingchang Mi Xiaotang Ma Zhijian Xiao | 2011 | Leukemia & Lymphoma2011，，9： | 1 |
| 9 | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China:a retrospective multicenter study显示文摘Objective:Evidence on the prognostic value of autologous stem cell transplantation(ASCT)and minimal residual disease(MRD)dynamics of patients with newly diagnosed multiple myeloma(NDMM)in China is limited.Our objective in the current study was to understand the current care paradigm and outcomes of these patients.Methods:This longitudinal cohort study used historical data from three top-tier hematologic disease care hospitals that contributed to the National Longitudinal Cohort of Hematological Diseases-Multiple Myeloma.Treatment regimens[proteasome inhibitor(PI)-,immunomodulatory drug(IMiD)-,PI+IMiD-based,and conventional],post-induction response,ASCT and MRD status,and survival outcomes[progression-free survival(PFS)and overall survival(OS)]were evaluated.Results:In total,454 patients with NDMM were included(median age,57 years;59.0%males)with a median follow-up of 58.7 months.The overall response rate was 91.0%,83.9%,90.6%,and 60.9%for PI-,IMiD-,PI+IMiD-based,and conventional regimens,respectively.Patients with ASCT during first-line therapy(26.2%)had a longer PFS and OS than patients who did not receive ASCT[median PFS,42.9 vs.21.2 months,P<0.001;median OS,not reached(NR)vs.65.8 months,P<0.001].The median OS was NR,71.5,and 56.6 months among patients with sustained MRD negativity,loss of MRD negativity,and persistent MRD,respectively(P<0.001).Multivariate analysis revealed that the lactic dehydrogenase level,International Staging System stage,extra-medullary disease,and upfront ASCT were independent factors in predicting OS among NDMM patients.Conclusions:Our study showed that novel agent-based regimens,first-line ASCT,and sustained MRD negativity were associated with a superior outcome for patients with NDMM in China(Identifier:NCT04645199). | Huishou Fan Weida Wang Ya Zhang Jianxiang Wang Tao Cheng Lugui Qiu Xin Wang Zhongjun Xia Gang An | 2023 | Cancer Biology & Medicine2023，20，1： | 1 |
| 10 | Immunotherapy for multiple myeloma: new chances and hope显示文摘Introduction Multiple myeloma(MM),characterized by the proliferation of monoclonal plasma cells in the bone marrow,has the second highest incidence among hematologic malignancies1.Because of its incurable nature,treatments for MM are aimed primarily at obtaining minimal residual disease(MRD)negativity and achieving persistent control,both of which are believed to be important strategies to prolong survival and improve prognosis in patients with MM. | Jingyu Xu Gang An Lugui Qiu | 2023 | Cancer Biology & Medicine2023，20，10： | 0 |
| 11 | Passion for moments and compassion for patients: in memory of Dr. Jianfeng Zhou (1966–2022)显示文摘At 11:37 on March 27,2022,Dr.Jianfeng Zhou,a renowned hematologist in China and a leader in the field of CAR-T treat-ment in hematological tumors,died unexpectedly at the age of 56 because of sudden coronary dissection rupture(acute myo-cardial infarction secondary to spontaneous coronary artery dissection).I have known Jianfeng for>20 years(Figs.1 and 2),he was one of the most outstanding,compassionate,and hard-work-ing clinician-scientist I have come across with.He dedicated his career to improving healthcare outcomes for every patient in his care,as well as to medical innovations that brought novel treatments to hundreds of thousands more patients. | Lugui Qiu Weiping Yuan Gang Huang Liang Huang | 2022 | Blood Science2022，4，3： | 0 |
| 12 | An Open-Label Study of Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population显示文摘OBJECTIVE Though doxorubicin is highly activein the treatment of multiple myeloma, its toxicityprofile limits its therapeutic index. We performed thisstudy to evaluate the efficacy and safety of pegylatedliposomal doxorubicin (PLD, Caelyx^(?)), vincristine,and reduced-dose dexamethasone combinationtherapy in newly diagnosed multiple myeloma (MM)patients in a Chinese population.METHODS This was an open-label, single-armstudy in which newly diagnosed patients with MMreceived PLD 40 mg/m^2 intravenously on Day 1,vincristine 1.4 mg/m^2 intravenously (maximum 2 mg)on Day 1, and 40 mg of dexarnethasone (intravenouslyor orally) from Day 1 to Day 4. Treatment wasrepeated every 28 days for at least 4 cycles.RESULTS In the intent-to-treat (ITT) analysis, theoverall response rate was 68.29%, and the completeremission rate was 10.98%. The incidence of alladverse events was 46.34%. The most commonnon-hematologic toxicities were palmar-plantarerythrodysesthesia (13.4%) and stomatitis (6.1%).CONCLUSION PLD, vincristine, and a reduceddosedexamethasone combination (DVd) is aneffective and safe regimen in newly diagnosed MMpatients in a Chinese population. | Yang Shen Zhixiang Shen Bin Jiang Jian Hou Rong Zhan Lugui Qiu Daobin Zhou Jie Jin Juan Li Fanyi Meng Ping Zou Ting Liu Jianyong Li Chun Wang Depei Wu Jun Ma | 2009 | Clinical oncology and cancer resexreh2009，6，6： | 0 |
| 13 | Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma显示文摘MicroRNAs(MiRNAs)carried by exosomes play pivotal roles in the crosstalk between cell components in the tumor microenvironment.Our study aimed at identifying the expression profile of exosomal miRNAs(exo-miRNAs)in the serum of multiple myeloma(MM)patients and investigating the regulation networks and their potential functions by integrated bioinformatics analysis.Exosomes in serum from 19 newly diagnosed MM patients and 9 healthy donors were isolated and the miRNA profile was investigated by small RNA sequencing.Differential expression of exo-miRNAs was calculated and target genes of miRNAs were predicted.CytoHubba was applied to identify the hub miRNAs and core target genes.The LASSO Cox regression model was used to develop the prognostic model,and the ESTIMATE immune score was calculated to investigate the correlation between the model and immune status in MM patients.The top six hub differentially expressed serum exo-miRNAs were identified.513 target genes of the six hub exo-miRNAs were confirmed to be differentially expressed in MM cells in the Zhan Myeloma microarray dataset.Functional enrichment analysis indicated that these target genes were mainly involved in mRNA splicing,cellular response to stress,and deubiquitination.13 core exo-miRNA target genes were applied to create a novel prognostic signature to provide risk stratification for MM patients,which is associated with the immune microenvironment of MM patients.Our study comprehensively investigated the exo-miRNA profiles in MM patients.A novel prognostic signature was constructed to facilitate the risk stratification of MM patients with distinct outcomes. | Teng Fang Hao Sun Xiyue Sun Yi He Peixia Tang Lixin Gong Zhen Yu Lanting Liu Shiyi Xie Tingyu Wang Zhenshu Xu Shuhua Yi Gang An Yan Xu Guoqing Zhu Lugui Qiu Mu Hao | 2023 | Blood Science2023，5，3： | 0 |
| 14 | Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma显示文摘Rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIPI)risk group is still confusing.We performed a retrospective analysis of the effect of RM treatments in patients with FL responding to induction therapy based on their FLIPI risk assessment carried out prior to treatment.We identified 93 patients between 2013 and 2019 who received RM every 3 months for≥4 doses(RM group),and 60 patients who did not accept RM or received rituximab less than 4 doses(control group).After a median follow-up of 39 months,neither median overall survival(OS)nor PFS was reached for the entire population.The PFS was significantly prolonged in the RM group compared to the control group(median PFS NA vs 83.1 months,P=.00027).When the population was divided into the 3 FLIPI risk groups,the PFS differed significantly(4-year PFS rates,97.5%vs 88.8%vs 72.3%,P=.01)according to group.There was no significant difference in PFS for FLIPI low-risk patients with RM compared to the control group(4-year PFS rates,100%vs 93.8%,P=.23).However,the PFS of the RM group was significantly prolonged for FLIPI intermediate-risk(4-year PFS rates,100%vs 70.3%,P=.00077)and high-risk patients(4-year PFS rates,86.7%vs 57.1%,P=.023).These data suggest that standard RM significantly prolongs the PFS of patients assigned to intermediate-and high-risk FLIPI groups but not to low-risk FLIPI group,and pending larger-scale studies to validate. | Ru Li Tingyu Wang Rui Lyv Yi Wang Ying Yu Yuting Yan Qi Sun Wenjie Xiong Wei Liu Weiwei Sui Wenyang Huang Huijun Wang Chengwen Li Jun Wang Dehui Zou Gang An Jianxiang Wang Lugui Qiu Shuhua Yi | 2023 | Blood Science2023，5，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员